Zevra Therapeutics Inc
ZVRA11.250USD
+0.140+1.26%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
615.14MCap. mercado
PérdidaP/E TTM
Más Datos de Zevra Therapeutics Inc Compañía
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.
Información de la empresa
Símbolo de cotizaciónZVRA
Nombre de la empresaZevra Therapeutics Inc
Fecha de salida a bolsaApr 16, 2015
Director ejecutivoMr. Neil F. Mcfarlane
Número de empleados59
Tipo de seguridadOrdinary Share
Fin del año fiscalApr 16
Dirección1180 Celebration Boulevard
CiudadCELEBRATION
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal34747
Teléfono13219393416
Sitio Webhttps://zevra.com/
Símbolo de cotizaciónZVRA
Fecha de salida a bolsaApr 16, 2015
Director ejecutivoMr. Neil F. Mcfarlane
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Alvin Shih, M.D.
Dr. Alvin Shih, M.D.
Independent Director
Independent Director
--
--
Dr. Adrian Quartel, M.D.
Dr. Adrian Quartel, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Tamara A. (Seymour) Favorito, CPA
Ms. Tamara A. (Seymour) Favorito, CPA
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Corey Watton
Mr. Corey Watton
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Neil F. Mcfarlane
Mr. Neil F. Mcfarlane
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
191.52K
+35.33%
Mr. John B. Bode
Mr. John B. Bode
Independent Director
Independent Director
40.00K
--
Mr. Joshua Schafer
Mr. Joshua Schafer
Executive Vice President - Business Development, Chief Commercial Officer
Executive Vice President - Business Development, Chief Commercial Officer
28.33K
-27.04%
Dr. Wendy L. Dixon, Ph.D.
Dr. Wendy L. Dixon, Ph.D.
Independent Director
Independent Director
--
-100.00%
Mr. Thomas D. (Tom) Anderson
Mr. Thomas D. (Tom) Anderson
Independent Director
Independent Director
--
--
Mr. R. LaDuane Clifton, CPA
Mr. R. LaDuane Clifton, CPA
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Desglose de ingresos
FY2024
FY2023
FY2022
FY2021
FY2020
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
23.61M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 16 de may
Actualizado: vie., 16 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
Accionistas
Accionistas
Proporción
Woodline Partners LP
8.44%
BlackRock Institutional Trust Company, N.A.
6.92%
Adage Capital Management, L.P.
6.62%
The Vanguard Group, Inc.
5.17%
Fidelity Management & Research Company LLC
4.00%
Other
68.85%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
24.22%
Investment Advisor
22.55%
Investment Advisor/Hedge Fund
14.58%
Research Firm
1.43%
Private Equity
1.25%
Individual Investor
0.71%
Venture Capital
0.33%
Bank and Trust
0.11%
Pension Fund
0.06%
Other
34.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
239
35.69M
65.27%
-2.27M
2025Q1
252
39.54M
72.42%
-1.74M
2024Q4
247
37.53M
70.32%
+3.07M
2024Q3
232
32.67M
61.46%
+11.34M
2024Q2
214
19.77M
45.38%
+395.88K
2024Q1
213
17.66M
40.45%
-265.50K
2023Q4
207
16.32M
37.86%
+175.17K
2023Q3
203
14.77M
38.14%
-620.11K
2023Q2
208
12.57M
36.97%
-1.13M
2023Q1
207
10.52M
30.95%
-2.74M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Woodline Partners LP
4.62M
8.44%
+476.03K
+11.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.78M
6.92%
+18.09K
+0.48%
Mar 31, 2025
Adage Capital Management, L.P.
3.62M
6.62%
-32.00K
-0.88%
Mar 31, 2025
The Vanguard Group, Inc.
2.83M
5.17%
+1.63K
+0.06%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.19M
4%
-15.70K
-0.71%
Mar 31, 2025
Nantahala Capital Management, LLC
1.47M
2.69%
-868.40K
-37.11%
Mar 31, 2025
Altium Capital Management LP
1.29M
2.35%
-562.67K
-30.41%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.23M
2.26%
+44.99K
+3.79%
Mar 31, 2025
683 Capital Management LLC
1.23M
2.24%
--
--
Mar 31, 2025
Rubric Capital Management LP
1.22M
2.23%
+601.61K
+97.64%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Simplify Propel Opportunities ETF
1.92%
iShares Neuroscience and Healthcare ETF
1.17%
SPDR S&P Pharmaceuticals ETF
0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.35%
iShares Micro-Cap ETF
0.11%
Invesco Nasdaq Biotechnology ETF
0.05%
iShares Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.03%
Ver más
Simplify Propel Opportunities ETF
Proporción1.92%
iShares Neuroscience and Healthcare ETF
Proporción1.17%
SPDR S&P Pharmaceuticals ETF
Proporción0.49%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.35%
iShares Micro-Cap ETF
Proporción0.11%
Invesco Nasdaq Biotechnology ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.05%
ProShares Ultra Nasdaq Biotechnology
Proporción0.05%
Vanguard US Momentum Factor ETF
Proporción0.04%
iShares Russell 2000 Growth ETF
Proporción0.03%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
